埃弗受体A7是一种可溶性瘤抑制剂,用于卵泡淋巴瘤
Elisa Oricchio1, Gouri Nanjangud, Andrew L Wolfe
1Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Cell
|November 1, 2011
概括
埃弗林受体A7 (EPHA7) 在毛囊性淋巴瘤 (FL) 中充当瘤抑制剂. 一种变体,EPHA7(TR),通过阻断癌症信号和减少瘤生长,显示出治疗潜力.
科学领域:
- 在瘤学瘤学.
- 癌症遗传学 癌症遗传学
- 分子生物学分子生物学
背景情况:
- 毛囊淋巴瘤 (FL) 遗传学提供了治疗点.
- 识别新型瘤抑制剂对于FL治疗至关重要.
研究的目的:
- 在卵泡淋巴瘤中识别新的瘤抑制剂.
- 探索弗朗西斯州埃弗林受体A7 (EPHA7) 的治疗潜力.
主要方法:
- 与基因选器交叉引用染色体变化.
- 使用小鼠FL模型来评估EPHA7的功能.
- 调查EPHA7 (EPHA7(TR)) 的一种可溶性拼接变体的抗癌活性.
主要成果:
- EPHA7被确定为一种瘤抑制剂,被6q删除所准,并在72%的FL中被禁用.
- 在小鼠模型中,EPHA7 Knockdown加速了淋巴瘤的发展.
- EPHA7 ((TR) 阻断瘤信号,并在异种移植模型中表现出抗瘤作用.
- EPHA7 ((TR) 与rituximab的融合使得向淋巴瘤的向输送成为可能.
结论:
- EPHA7是毛囊淋巴瘤中的关键瘤抑制剂.
- 可溶性EPHA7 (TR) 变种显示出显著的治疗潜力.
- 将基因组学与功能屏幕相结合是发现癌症治疗方法的强大方法.
相关概念视频
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...


